About
Overview
Management Team
Board of Directors
Scientific Advisory Board
CEO Corner
Partnering
Science
Pipeline
Ampligen
®
Immuno-Oncology
Immune Disorders
Viral Diseases
Orphan Drug Designation
Scientific Publications
Clinical Trials
Immuno-Oncology
Immune Disorders
Viral Diseases
Investors
Overview
Press Releases
Company Info
Profile
Management Team
Presentations
Events
Stock Information
SEC Filings
Analyst Coverage
Corporate Governance
Governance Documents
Board of Directors
Committee Composition
Stockholder Meeting
Email Alerts
Investor Contact
Contact Us
Select Page
Science
Search
Search
Recent Posts
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
Recent Comments
No comments to show.